Infliximab

Chimeric (mouse/human) monoclonal antibody against TNF-alpha

• ·Hematopoietic and Lymphoid Cell Neoplasm
• ·Malignant Solid Neoplasm
• ·Steroid-Refractory Pneumonitis
• ·Melanoma
• ·Inflamatory Bowel Disease (Crohn's and Ulcerative Colitis)

Therapeutic range

3–10 ug/mL

Ctrough > 3-7 ug/mL for IBD

No curated interaction pairs are recorded for Infliximab. This is not a statement that none exist — check a full interaction reference before combining.

• Infusion reactions
• Infections
• Headache
• Abdominal pain

Half-life

7.7-9.5 days

Protein binding

N/A

Metabolised by

Proteolytic degradation

Clearance

0.015 L/h

adult IBD and RA patients

Volume of distribution

3 L

Renally eliminated

0%

Model

2-compartment

Not recorded for Infliximab. Absence here means this database does not hold a category — not that the drug is safe in pregnancy or breastfeeding.